// App-Quantinova.ai

3027 : Dual inhibition of PKC and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma

Researchers

Presenter

  • Guillaume Carita

Principal Investigators

  • Estelle Frisch Dit Leitz

  • Ahmed Dahmani

  • Chloe Raymondie

  • Nathalie Cassoux

  • Sophie Piperno-Neumann

  • Fariba Nemati

  • Ensar Halilovic

  • Sebastien Jeay

  • Andrew Wylie

  • Caroline Emery

  • Sergio Roman-Roman

  • Marie Schoumacher

  • Didier Decaudin

Medical Centers

  • Curie, Paris, France

  • Novartis, Cambridge, MA

Locations

  • France

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Uveal melanoma

  • Solid malignancies

Biomarkers

  • G Protein Subunit Alpha 11

  • G protein subunit alpha q

Drug/Treatment

  • Sotrastaurin

  • Binimetinib

  • Everolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved